Peripheral artery disease

BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease

Retrieved on: 
Monday, February 12, 2024
BDX, Peripheral artery disease, Computer data storage

FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.

Key Points: 
  • FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.
  • The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy, with this installment highlighting the Peripheral Vascular Disease platform within the BD Peripheral Intervention business unit.
  • The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com.
  • A replay of the event will be available on the same webpage following its conclusion.

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

Retrieved on: 
Monday, February 12, 2024
Other Health, Research, Radiology, Medical Devices, Clinical Trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Diabetes, Physician, Clinical trial, Hospital, PAD, Patient, Trial of the century, Peripheral artery disease, Stroke, Medical imaging

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).

Key Points: 
  • Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).
  • Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.
  • The clinical trial, named SEPARATE, is designed to assess the Clotild® sensor's capability to detect various characteristics of blood vessel blockages in PAD patients.
  • A key focus of the SEPARATE clinical trial is to evaluate the Clotild® sensor's capacity in differentiating between soft and friable "fresh" clots and organized "old" clots.

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

Retrieved on: 
Friday, February 9, 2024
MD, FDA, Food, HAV, Injury, Defense, Diagnosis, Sale, Amputation, PDUFA, Peripheral artery disease, Surgeon, Infection, Patient, Priority review, BLA, Regenerative medicine, Doctor of Philosophy, HUMA, Pharmaceutical industry

DURHAM, N.C., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible.

Key Points: 
  • This targeted PDUFA date is based on the Priority Review grant, which is a mechanism reserved by FDA for products that, if approved, would significantly improve the treatment, diagnosis, or prevention of serious conditions.
  • Priority Review applications have a six-month review time instead of ten months for a standard review.
  • The Priority Review aligns with the Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA in May 2023 for urgent arterial repair following extremity vascular trauma.
  • The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024
Pulse, Interventional radiology, Health equity, SCAI, Society for Vascular Surgery, Pain, Peripheral artery disease, MD Anderson Cancer Center, Prevalence, Interventions, SIR, University, Heart, Health, Amputation, Society, Diabetes, Heated tobacco product, Smoker, Risk, Patient, Leg, Rest, Vascular disease, Society of Interventional Radiology, PAD, Walking, MBA, Association of Black Cardiologists, Doctor of Philosophy

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member

Retrieved on: 
Thursday, February 1, 2024
Emerald, Multimedia, Surgeon, Ageing, Knowledge, Aneurysm, Family, Vein, Henry Ford Hospital, Artery, Varicose veins, Southern Methodist University, Society, Patient, Philosophy, ABS, Hartford Hospital, Mentorship, Council, Aortic aneurysm, Medical degree, Journal, Dialysis, Education, Moyamoya disease, Methodist University, Stroke, Blood, Peripheral artery disease, University, Inner circle, Private practice, Nursing

PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysms; and peripheral artery disease surgery.

Dr. Paul Gagne Assumes Expanded Role as Chief of Clinical Operations and Research at Mangrove Management Partners

Retrieved on: 
Thursday, January 25, 2024
Health, Hospitals, Surgery, Health Technology, Managed Care, Cardiology, Thigh, Patient, Vascular disease, Multimedia, Culture, Peripheral artery disease, Diagnosis, Vein, Mangrove, Lead, Nursing

The Vascular Care Group (“TVCG”) and Mangrove Management Partners (“Mangrove”, the affiliated management company of TVCG), announced today that Dr. Paul Gagne, will assume an expanded leadership role as Chief of Clinical Operations and Research.

Key Points: 
  • The Vascular Care Group (“TVCG”) and Mangrove Management Partners (“Mangrove”, the affiliated management company of TVCG), announced today that Dr. Paul Gagne, will assume an expanded leadership role as Chief of Clinical Operations and Research.
  • In this capacity, Dr. Paul Gagne will further lead and enhance clinical operations and research initiatives, with a strong focus on improving standardization of care and clinical outcomes.
  • View the full release here: https://www.businesswire.com/news/home/20240125875620/en/
    Dr. Paul Gagne, Mangrove Management Partners and The Vascular Care Group (Photo: Business Wire)
    Dr. Paul Gagne is an internationally recognized expert in the field of vascular surgery, including with respect to venous disease.
  • "We are excited to announce Dr. Gagne's expanded role as Chief of Clinical Operations and Research," said Mark Rowe, CEO of Mangrove Management Partners.

Life Line Screening Announces Expansion of 250+ Preventive Heart Health and Stroke Risk Screening Events for 2024

Retrieved on: 
Monday, January 8, 2024
Technology, Men, Managed Care, General Health, Science, Consumer, Cardiology, Other Communications, Health, Other Science, Research, Other Technology, Telemedicine, Virtual Medicine, Communications, Other Health, Women, Seniors, Life Line Screening, Stroke, Peripheral artery disease, Lifeline, Risk, Multimedia, Aortic aneurysm, Atrial fibrillation, History

Life Line Screening, the nation's leading provider of mobile preventive heart health and stroke risk screenings announced their expansion of cardiovascular screening events to more local communities throughout the United States for 2024.

Key Points: 
  • Life Line Screening, the nation's leading provider of mobile preventive heart health and stroke risk screenings announced their expansion of cardiovascular screening events to more local communities throughout the United States for 2024.
  • This expansion will bring the number of nationwide preventive health screening events to over 14,800, which will support approximately 700,000 people with understanding their cardiovascular health, risk of stroke, and more through Life Line Screening’s community-based ultrasound and phlebotomy testing.
  • More about Life Line Screening:
    Life Line Screening is the nation’s leading preventive health screening platform.
  • Life Line Screening's preventive health events are centered around vascular health, stroke prevention, metabolic health, oncology testing, and more.

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Artery, Heart, INN, Risk, Hypertension, Population, Embolism, Rivaroxaban, Moyamoya disease, Death, Thrombus, Coronary artery disease, Chest pain, Vein, Facial muscles, Anatomy, ACS, IIA, Knee, ATC, Clopidogrel, DVT, Bleeding, Disease, Ageing, Atrial fibrillation, ASA, Safety, Leg, Medical Subject Headings, Hip, Peripheral artery disease, Pulmonary embolism, Thrombin, Diabetes, International, CAD, Language, Ventricular fibrillation, Tablet, Select, Aspirin, Patient, Acute coronary syndrome, Coronary thrombosis, Blood, Brain, VTE, Recurrence, European Medicines Agency, Ticlopidine, Deep vein thrombosis, PAD, Generic drug

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

MedBright AI Announces Election of Two US Healthcare Experts to Board of Directors and Approval of New Share Class

Retrieved on: 
Tuesday, December 5, 2023
Olive, DDS, United States Naval Academy, Cardiology, Peripheral artery disease, Patient safety, Class, Freedom, FDA, Medical director, Person, RPVI, Yale University, FACC, Yale School of Medicine, MD, VMD, Moyamoya disease, Olive View–UCLA Medical Center, Investment, Artificial intelligence, Quality, News, Indian stock exchange, OTCQB, Coronary artery disease, Iraq War, HIPPA, Security (finance)

He has broad experience in medical systems management and healthcare start-ups.

Key Points: 
  • He has broad experience in medical systems management and healthcare start-ups.
  • She has over 25 years of experience as a dynamic, visionary leader in healthcare and the military.
  • Michael Dalsin, Chairman of the Investment Committee says, “Both Dr. Gerber and Dr. Wilks have a proven track record as leaders in healthcare services.
  • As a large shareholder, I was pleased to see their appointment to the Board of Directors.

North Star Vascular & Interventional Opens New Center in Minneapolis

Retrieved on: 
Wednesday, December 20, 2023
Technology, FDA, Health, Robotics, Other Health, Radiology, Surgery, Oncology, Practice Management, Medical Devices, Managed Care, General Health, Hospitals, Health Technology, Patient, Google Images, Varicocele, Artery, Pain management, Peripheral artery disease, Risk, Advocate Christ Medical Center, Knee, Physician, Uterine fibroid, Vascular disease, Intervention, Male, Infertility, Kidney disease, Chronic pain, Thyroid disease, Osteoarthritis, MBA, MD, Vein, Cancer, GE HealthCare, University, Moyamoya disease, Neoplasm, Rush University Medical Center, Fibroid, Interventional radiology, Liver cancer, Hospital-acquired infection, Pelvic congestion syndrome, Radiation, Y-90, Medical imaging

The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.

Key Points: 
  • The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.
  • North Star Vascular & Interventional (NSVI) offers minimally invasive procedures to treat health conditions such as peripheral artery and venous disease, cancer, enlarged prostate, uterine fibroids and more.
  • Jafar Golzarian, MD, FSIR, professor emeritus of interventional radiology at the University of Minnesota Medical School, has authored more than 400 academic articles and national and international lectures on interventional radiology.
  • Bulent Arslan, MD, FSIR is a Professor of Radiology and Chief of Interventional Radiology at the Rush University Medical Center in Chicago.